Nilotinib Zentiva Pharma Uk

Nilotinib, the active ingredient in Nilotinib Zentiva Pharma Uk, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in adult patients.

GNH USA supplies Nilotinib Zentiva Pharma Uk as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is indicated for the treatment of chronic myeloid leukemia, a BCR‑ABL driven hematologic malignancy. - Chronic myeloid leukemia (CML) – chronic phase: reduces disease progression and improves survival. - Chronic myeloid leukemia (CML) – accelerated phase: achieves hematologic and cytogenetic responses. - Chronic myeloid leukemia (CML) – blast phase: provides disease control when other therapies have failed. - CML after imatinib resistance: offers an alternative targeted therapy. - CML after imatinib intolerance: enables continued BCR‑ABL inhibition.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools, often transient. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Cardiovascular events: arterial occlusive disease, myocardial infarction. - Pancreatitis: inflammation of the pancreas, may be severe. - Severe hepatotoxicity: marked elevation of liver enzymes or hepatitis. - QT interval prolongation: risk of cardiac arrhythmia.

When prescribing Nilotinib, clinicians should observe several precautionary measures to minimize risk. - Cardiac monitoring: assess baseline ECG and monitor QT interval during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically thereafter. - Pancreatic enzymes: check amylase and lipase levels regularly. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy risk: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly raise Nilotinib levels. - Proton pump inhibitors (e.g., omeprazole) taken concurrently: may reduce absorption and efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, St. John’s wort): may lower drug exposure. - Antacids or H2‑blockers taken within 2 hours of Nilotinib: can affect bioavailability. - Anticoagulants (e.g., warfarin): may require INR monitoring due to possible interaction.